undamentalytics Newsletter
Sign in

Travere Therapeutics, Inc. revenue

Travere Therapeutics, Inc.'s revenue was $491m in fiscal 2025, up 110.5% on the year before. Since fiscal 2016 ($134m) it has grown at a compound 15.6% a year. Over the last twelve months it was $651m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Feb 20112012Feb 20122016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue00134155164175198132109145233491651
Growth on the year before———+16.0%+6.0%+6.8%+13.1%−33.5%−17.0%+32.7%+60.5%+110.5%—
Gross profit——129151159170192128105134225480641

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $410M 83.6% ▲ 81.1%
FILSPARI $322M 78.4% ▲ 143.5%
Tiopronin Products $88.5M 21.6% ▼ 6.4%
Licenses $80.3M 16.4% ▲ 1141.0%

From Travere Therapeutics, Inc.'s 10-K filed February 19, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Travere Therapeutics, Inc. $651m 49.4% 71.3%
Emergent Biosolutions Inc. $649m -17.7% -16.2%
Alvotech $586m 19.7% —
Amphastar Pharmaceuticals, Inc. $730m 1.0% 10.5%
Pacira Biosciences, Inc. $746m 5.7% 3.7%
Corcept Therapeutics Inc $831m 16.0% 24.7%

Compare with peers

Head to head: EBS vs TVTXALVO vs TVTXAMPH vs TVTXPCRX vs TVTX

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Travere Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Travere Therapeutics, Inc.